AVTX · Avalo Therapeutics, Inc. · Stock research

Current Thesis

The soft catalyst flagged in July coverage has come and gone. Avalo reported Q2 2026 on 2026-08-06 — a week after the date carried in the prior note — and what the release contained was a schedule: the registrational Phase 3 of abdakibart (AVTX-009) in moderate-to-severe hidradenitis suppurativa is guided to initiate in the first half of 2027, with the AVTX-010 IND on the same H1 2027 timeline. Net loss was $36.4M, or $(0.83) per share against a $(0.58) consensus estimate. Cash, cash equivalents and investments stood at $472.2M as of 2026-06-30, funding operations "into 2029."

That leaves a single-asset immunology name whose defining binary fired on 2026-05-05 and whose next one does not begin until 2027. The tape reflects it: the 2026-08-14 close of $19.59 is 14.3% under the $22.87 52-week high on the adjusted daily series, RSI(14) at 50.8, three-month return +10.4%. Sell-side stayed constructive but marked down — Guggenheim maintained Buy with the target cut to $48 and HC Wainwright maintained Buy with the target cut to $30, both on 2026-08-07. The narrative is maturing: well known, still holding its range, but with thinning new information between now and a Phase 3 start that is at least two quarters out. Nothing in the August print argues for chasing a mid-range quote; the constructive case requires the base to hold and re-accelerate on a dated regulatory or business-development event that does not currently exist on the calendar.

Bullish and bearish views on Avalo Therapeutics, Inc.

The model's bull view on Avalo Therapeutics, Inc. (AVTX), in brief: The efficacy question is answered. LOTUS topline (2026-05-05) hit HiSCR75 at Week 16 of 42.2% (150mg) and 42.9% (300mg) versus 25.6% placebo in >250 patients — a stricter endpoint than the HiSCR50 most HS programs headline. Cash is not the constraint near-term. $472.2M in cash… The bear view: A ten-month information gap. Phase 3 initiation is guided to H1 2027 (2026-08-06); topline from that program is years beyond it. Between now and then the flow is corporate — conference appearances, a congress presentation of full LOTUS data that the company has not dated, and… Both cases follow in full.

Bull Case

• The efficacy question is answered. LOTUS topline (2026-05-05) hit HiSCR75 at Week 16 of 42.2% (150mg) and 42.9% (300mg) versus 25.6% placebo in >250 patients — a stricter endpoint than the HiSCR50 most HS programs headline.
• Cash is not the constraint near-term. $472.2M in cash and investments as of 2026-06-30; net cash used in operating activities was $37.7M for the six months ended 2026-06-30 (Q2 release, 2026-08-06).
• Coverage remains uniformly constructive on rating. Four dated Buy/Outperform stances: B of A $35 (2026-06-12), Leerink $38 (2026-07-06), HC Wainwright $30 and Guggenheim $48 (both 2026-08-07). Every cited house that cut a target kept the rating.
• Passive holder base installed. Russell 2000/3000 inclusion effective 2026-06-26 added an index bid to a small share count — 43,602,044 weighted average shares in Q2 2026.
• Franchise, not one molecule. AVTX-010, a long-acting next-generation anti–IL-1β antibody, carries a guided H1 2027 IND (reiterated 2026-08-06), extending the mechanism beyond HS.
• Takeout optionality persists. A de-risked anti–IL-1β asset with $472.2M of cash and no partner is a structurally clean acquisition target in immuno-dermatology; no approach has been disclosed.

Bear Case

• A ten-month information gap. Phase 3 initiation is guided to H1 2027 (2026-08-06); topline from that program is years beyond it. Between now and then the flow is corporate — conference appearances, a congress presentation of full LOTUS data that the company has not dated, and quarterly reports.
• Spend is ramping ahead of the program. Q2 R&D was $23.4M, up $9.3M YoY; G&A $8.1M, up $2.9M YoY. The "into 2029" runway is stated for operations, and the cost of a full registrational Phase 3 plus any commercial build is what that balance has to absorb.
• Targets moving down while ratings stay put. Two cuts inside 24 hours of the print (2026-08-07), leaving a $30–$48 spread among the houses cited above — dispersion that wide is a disagreement about the discount rate on a 2027 start, not a consensus.
• Entrenched competition. Novartis' Cosentyx has been FDA-approved in HS since October 2023 and UCB's Bimzelx is established in the indication; Phase 3 must replicate 42% HiSCR75 against a 25.6% placebo rate to matter commercially.
• The re-rate has already happened. The move off the $4.61 52-week low was driven by one Phase 2 readout; what remains is execution and approval risk carried for four-plus quarters with no scheduled resolution.

Setup & Price Structure

• Reference close 2026-08-14: $19.59, -14.3% from the $22.87 52-week high on the adjusted series. RSI(14) 50.8 — neither extended nor washed out.
• Three-month return +10.4%: the post-print tape did not break, but it has not reclaimed the high either. The structure is a range, and the level that has framed the downside through this coverage is $16.
• Crowding observables, stated as observables: index inclusion effective 2026-06-26 installed passive holders in a name with 43.6M weighted average shares; four dated Buy-side targets cluster the sell-side on one side of the trade; two of those targets were cut on 2026-08-07. No insider transactions surfaced in the filings reviewed for this window.
• The financing observable to watch is a shelf takedown or ATM: R&D rose $9.3M YoY in the quarter before a Phase 3 that has not started.

Catalyst Calendar (next 30 days)

• 2026-08-16 → 2026-09-15: no company-confirmed dated event. The 30-day window is empty as of the 2026-08-06 Q2 release; the next scheduled corporate event is the Q3 report.
• ~2026-11-05 (est.): Q3 2026 report, extrapolated from the 2026-08-06 Q2 cadence. Watch for an end-of-Phase-2 regulatory interaction, Phase 3 protocol detail, and whether H1 2027 holds.

Elapsed catalysts

• Undated (guided 2026-08-06): presentation of full LOTUS Phase 2 results at a medical congress. The company has signalled a congress presentation without naming a venue or date; the autumn dermatology calendar is the plausible slot and would be the only chance for new clinical detail this year. (passed 20d ago)
• H1 2027 (company guidance, 2026-08-06): registrational Phase 3 initiation in HS, and AVTX-010 IND submission. (passed 20d ago)

What Would Change Our Mind

The structural break would be the range floor giving way: a weekly close below $16 would end the post-LOTUS consolidation that has held since the May re-rate and would say the market is repricing a 2027 start rather than waiting for it. Secondary confirmation would be the Q3 report (est. early November) passing with nothing but a reiteration of H1 2027 — no end-of-Phase-2 regulatory milestone, no partnership, no congress date — or additional target cuts, which would extend the pattern set on 2026-08-07.

What would flip the read the other way is equally specific: a dated Phase 3 start pulled into 2026, a disclosed FDA end-of-Phase-2 outcome, a named congress slot for the full LOTUS dataset, or a partnership that offloads Phase 3 cost. Any of those converts a calendar gap into a catalyst and would argue the theme is re-accelerating rather than maturing. A shelf takedown or ATM announcement into strength argues the opposite about how management views the cash against the program.

Correlation Notes

• Small-cap clinical-stage biotech beta: moves with XBI-type risk appetite and with the rate path, since the entire value sits in cash flows beyond 2029.
• Russell 2000/3000 membership since 2026-06-26 ties a portion of the float to small-cap index flows, independent of company news.
• Read-across is mechanistic rather than direct: HS competitive datapoints from Novartis (Cosentyx) and UCB (Bimzelx) reprice the commercial bar for abdakibart without touching Avalo's own trial.
• M&A sentiment in immuno-dermatology is the swing factor in the catalyst gap — sector takeouts at premiums support the optionality argument; a quiet deal tape leaves the name trading on flow.